HealthCue Biopharma's CUE-221 Achieves Phase 2 Success in Chronic Hives
Cue Biopharma announced positive topline results from a Phase 2a study of its drug CUE-221 in patients with moderate to severe chronic spontaneous urticaria, commonly known as chronic hives. The study demonstrated that CUE-221 met its Phase 2 goals, marking a significant step forward in treatment development for this condition.
Rttnews·


